open access

Vol 69, No 2 (2018)
Original Paper
Published online: 2017-12-20
Submitted: 2017-05-29
Accepted: 2017-10-30
Get Citation

Evaluation of adipokines in children with cystic fibrosis

Edyta Machura, Maria Szczepańska, Elżbieta Świętochowska, Franciszek Halkiewicz, Małgorzata Barć-Czarnecka, Katarzyna Ziora, Dariusz Ziora
DOI: 10.5603/EP.a2018.0007
·
Pubmed: 29465158
·
Endokrynologia Polska 2018;69(2):128-134.

open access

Vol 69, No 2 (2018)
Original Paper
Published online: 2017-12-20
Submitted: 2017-05-29
Accepted: 2017-10-30

Abstract

Introduction: Patients with CF present numerous pathological conditions such as malnutrition, depletion of fat-free mass, metabolic disturbances (abnormal glucose metabolism, increased insulin resistance, chronic energy deficit, local and chronic inflammation), which could affect or be associated with altered adipokines concentration Material and Methods: We aimed in this study to investigate the levels of selected adipokines such as resistin, apelin, adiponectin to demonstrate their application as possible markers of inflammation. Results: Serum level of resistin was higher (p < 0.001) and adiponectin - lower (p=0.02) in CF children than in healthy children. There was no difference in serum apelin level between two examined groups. However, values of adiponectin/BMI and apelin/BMI ratios in CF did not differ significantly from controls. Higher values of resistin/BMI ratio in CF in comparison to controls were observed Serum resistin/adiponectin ratio was significantly higher in CF patients than in controls (p < 0.0001). Resistin/BMI ratio correlated negatively with FEV1 (R:-48,p < 0.043). Serum resistin/adiponectin ratio correlated negatively with FEV1/FVC (R:-49, p=0.04), Adipokines showed no correlation with BMI and BMI-SDS, glucose, total cholesterol, and LDL-, HDL-cholesterol, triglyceride serum levels. Spirometric parameters FEV1, FVC, VC correlated negatively with serum glucose levels (R: -0.55, p < 0.018; R: -0.65 p < 0.0025; R:-0.76, p < 0.0008 respectively). FEV1 and FVC correlated positively with BMI-SDS (R:0.58, p < 0.01; R:0.5, p < 0.036, respectively). Conclusions: A significant increase in resistin concentration expressed also as resistin/BMI, and resistin/adiponectin ratios, observed in children with CF may suggests that this adipokine is involved in the inflammatory process underlying the disease and is related to worse spirometric parameters describing airways obstruction.

Abstract

Introduction: Patients with CF present numerous pathological conditions such as malnutrition, depletion of fat-free mass, metabolic disturbances (abnormal glucose metabolism, increased insulin resistance, chronic energy deficit, local and chronic inflammation), which could affect or be associated with altered adipokines concentration Material and Methods: We aimed in this study to investigate the levels of selected adipokines such as resistin, apelin, adiponectin to demonstrate their application as possible markers of inflammation. Results: Serum level of resistin was higher (p < 0.001) and adiponectin - lower (p=0.02) in CF children than in healthy children. There was no difference in serum apelin level between two examined groups. However, values of adiponectin/BMI and apelin/BMI ratios in CF did not differ significantly from controls. Higher values of resistin/BMI ratio in CF in comparison to controls were observed Serum resistin/adiponectin ratio was significantly higher in CF patients than in controls (p < 0.0001). Resistin/BMI ratio correlated negatively with FEV1 (R:-48,p < 0.043). Serum resistin/adiponectin ratio correlated negatively with FEV1/FVC (R:-49, p=0.04), Adipokines showed no correlation with BMI and BMI-SDS, glucose, total cholesterol, and LDL-, HDL-cholesterol, triglyceride serum levels. Spirometric parameters FEV1, FVC, VC correlated negatively with serum glucose levels (R: -0.55, p < 0.018; R: -0.65 p < 0.0025; R:-0.76, p < 0.0008 respectively). FEV1 and FVC correlated positively with BMI-SDS (R:0.58, p < 0.01; R:0.5, p < 0.036, respectively). Conclusions: A significant increase in resistin concentration expressed also as resistin/BMI, and resistin/adiponectin ratios, observed in children with CF may suggests that this adipokine is involved in the inflammatory process underlying the disease and is related to worse spirometric parameters describing airways obstruction.
Get Citation

Keywords

cystic fibrosis, adipokines, resistin, apelin, adiponectin, children, inflammation

About this article
Title

Evaluation of adipokines in children with cystic fibrosis

Journal

Endokrynologia Polska

Issue

Vol 69, No 2 (2018)

Pages

128-134

Published online

2017-12-20

DOI

10.5603/EP.a2018.0007

Pubmed

29465158

Bibliographic record

Endokrynologia Polska 2018;69(2):128-134.

Keywords

cystic fibrosis
adipokines
resistin
apelin
adiponectin
children
inflammation

Authors

Edyta Machura
Maria Szczepańska
Elżbieta Świętochowska
Franciszek Halkiewicz
Małgorzata Barć-Czarnecka
Katarzyna Ziora
Dariusz Ziora

References (34)
  1. De Boeck K, Wilschanski M, Castellani C, et al. Diagnostic Working Group. Cystic fibrosis: terminology and diagnostic algorithms. Thorax. 2006; 61(7): 627–635.
  2. Sagel SD, Wagner BD, Anthony MM, et al. Sputum biomarkers of inflammation and lung function decline in children with cystic fibrosis. Am J Respir Crit Care Med. 2012; 186(9): 857–865.
  3. Cohen-Cymberknoh M, Kerem E, Ferkol T, et al. Airway inflammation in cystic fibrosis: molecular mechanisms and clinical implications. Thorax. 2013; 68(12): 1157–1162.
  4. Dhaliwal J, Leach S, Katz T, et al. Intestinal inflammation and impact on growth in children with cystic fibrosis. J Pediatr Gastroenterol Nutr. 2015; 60(4): 521–526.
  5. Moriconi N, Kraenzlin M, Müller B, et al. Body composition and adiponectin serum concentrations in adult patients with cystic fibrosis. J Clin Endocrinol Metab. 2006; 91(4): 1586–1590.
  6. Wang C. Obesity, inflammation, and lung injury (OILI): the good. Mediators Inflamm. 2014; 2014: 978463.
  7. Ouchi N, Parker JL, Lugus JJ, et al. Adipokines in inflammation and metabolic disease. Nat Rev Immunol. 2011; 11(2): 85–97.
  8. Misra M, Klibanski A. Endocrine consequences of anorexia nervosa. The Lancet Diabetes & Endocrinology. 2014; 2(7): 581–592.
  9. Olveira G, Olveira C, Gaspar I, et al. Fat-free mass depletion and inflammation in patients with bronchiectasis. J Acad Nutr Diet. 2012; 112(12): 1999–2006.
  10. Steppan CM, Bailey ST, Bhat S, et al. The hormone resistin links obesity to diabetes. Nature. 2001; 409(6818): 307–312.
  11. Holcomb IN, Kabakoff RC, Chan B, et al. FIZZ1, a novel cysteine-rich secreted protein associated with pulmonary inflammation, defines a new gene family. EMBO J. 2000; 19(15): 4046–4055.
  12. Fantuzzi G. Adiponectin and inflammation: consensus and controversy. J Allergy Clin Immunol. 2008; 121(2): 326–330.
  13. Tatemoto K, Hosoya M, Habata Y, et al. Isolation and characterization of a novel endogenous peptide ligand for the human APJ receptor. Biochem Biophys Res Commun. 1998; 251(2): 471–476.
  14. Kleinz MJ, Davenport AP. Emerging roles of apelin in biology and medicine. Pharmacol Ther. 2005; 107(2): 198–211.
  15. Bełtowski J. Apelin and visfatin: unique. Med Sci Monit. 2006; 12(6): RA112–RA119.
  16. Boucher J, Masri B, Daviaud D, et al. Apelin, a newly identified adipokine up-regulated by insulin and obesity. Endocrinology. 2005; 146(4): 1764–1771.
  17. Kawamata Y, Habata Y, Fukusumi S, et al. Molecular properties of apelin: tissue distribution and receptor binding. Biochim Biophys Acta. 2001; 1538(2-3): 162–171.
  18. Wang G, Anini Y, Wei W, et al. Apelin, a new enteric peptide: localization in the gastrointestinal tract, ontogeny, and stimulation of gastric cell proliferation and of cholecystokinin secretion. Endocrinology. 2004; 145(3): 1342–1348.
  19. Xie H, Tang Sy, Cui Rr, et al. Apelin and its receptor are expressed in human osteoblasts. Regul Pept. 2006; 134(2-3): 118–125.
  20. Kleinz MJ, Skepper JN, Davenport AP. Immunocytochemical localisation of the apelin receptor, APJ, to human cardiomyocytes, vascular smooth muscle and endothelial cells. Regul Pept. 2005; 126(3): 233–240.
  21. Ziai S, Belson L, Malet A, et al. The association between leptin and insulin levels in adults with cystic fibrosis. Diabetes Metab. 2012; 38(1): 34–39.
  22. Cohen RI, Tsang D, Koenig S, et al. Plasma ghrelin and leptin in adult cystic fibrosis patients. J Cyst Fibros. 2008; 7(5): 398–402.
  23. Smyth AR, Bell SC, Bojcin S, et al. European Cystic Fibrosis Society. European Cystic Fibrosis Society Standards of Care: Best Practice guidelines. J Cyst Fibros. 2014; 13 Suppl 1: S23–S42.
  24. Kawanami D, Maemura K, Takeda N, et al. Direct reciprocal effects of resistin and adiponectin on vascular endothelial cells: a new insight into adipocytokine–endothelial cell interactions. Biochemical and Biophysical Research Communications. 2004; 314(2): 415–419.
  25. Ballantyne D, Scott H, MacDonald-Wicks L, et al. Resistin is a predictor of asthma risk and resistin:adiponectin ratio is a negative predictor of lung function in asthma. Clin Exp Allergy. 2016; 46(8): 1056–1065.
  26. Kumor‑Kisielewska A, Kierszniewska‑Stępień D, Pietras T, et al. Assessment of leptin and resistin levels in patients with chronic obstructive pulmonary disease. Polish Archives of Internal Medicine. 2013; 123(5): 215–220.
  27. Bianco A, Nigro E, Monaco ML, et al. The burden of obesity in asthma and COPD: Role of adiponectin. Pulm Pharmacol Ther. 2017; 43: 20–25.
  28. Panagopoulou P, Fotoulaki M, Manolitsas A, et al. Adiponectin and body composition in cystic fibrosis. J Cyst Fibros. 2008; 7(3): 244–251.
  29. Ziai S, Elisha B, Hammana I, et al. Normal total and high molecular weight adiponectin levels in adults with cystic fibrosis. J Cyst Fibros. 2011; 10(6): 483–486.
  30. Hammana I, Malet A, Costa M, et al. Normal adiponectin levels despite abnormal glucose tolerance (or diabetes) and inflammation in adult patients with cystic fibrosis. Diabetes Metab. 2007; 33(3): 213–219.
  31. Lavie M, Fisher D, Vilozni D, et al. Glucose intolerance in cystic fibrosis as a determinant of pulmonary function and clinical status. Diabetes Res Clin Pract. 2015; 110(3): 276–284.
  32. Berry M, Brightling C, Pavord I, et al. TNF-alpha in asthma. Curr Opin Pharmacol. 2007; 7(3): 279–282.
  33. Szadkowska A. Adipokiny [W:] Urban M. red Miażdżyca u dzieci i młodzieży. Cornetis wyd 1 2007: 268–285.
  34. Mądry E, Nowak J, Wykrętowicz A, et al. Predicting the risk of atherosclerosis in patients with cystic fibrosis – rationale and design of a prospective cohort study. JMed Sci. 2015; 2: 126–128.

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Via MedicaWydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl